Disease activity indices and daily dosage of prednisone equivalent over time.
| Baseline (T0), n = 26 | 1 Month (T4), n = 26 | 3 Months (T12), n = 24 | 6 Months (T24), n = 19 | 9 Months (T36), n = 13 | P* | |
|---|---|---|---|---|---|---|
| SLEDAI-2K | 7.5 (6-10) | 6.0 (4-8) | 5.5 (2-7) | 2 (1-4) | 2 (0-2) | T0 vs T4: 0.01 T0 vs T12: 0.003 T0 vs T24: < 0.001 T0 vs T36: 0.002 |
| SLE-DAS | 6.7 (5.3-13.2) | 5.2 (4.0-6.8) | 3.1 (1.3-5.7) | 1.3 (1.1-3.0) | 1.1 (0.6-2.3) | T0 vs T4: 0.01 T0 vs T12: 0.001 T0 vs T24: < 0.001 T0 vs T36: 0.002 |
| CLASI-Aa | 12 (7-22) | 4 (2-9) | 2 (1-5) | 0 (0-4) | 0 (0-0) | T0 vs T4: < 0.001 T0 vs T12: < 0.001 T0 vs T24: < 0.001 T0 vs T36: 0.01 |
| TJCb | 6 (3-10) | 4 (2-10) | 2 (0-8) | 0 (0-3) | 0 (0-1) | T0 vs T4: 0.03 T0 vs T12: NS T0 vs T24: NS T0 vs T36: 0.01 |
| SJCb | 2 (0-4) | 1 (0-2) | 0 (0-1) | 0 (0-0) | 0 (0-0) | T0 vs T4: 0.02 T0 vs T12: 0.02 T0 vs T24: 0.04 T0 vs T36: 0.04 |
| PGA (0-3) | 1.0 (1.0-1.6) | 1.0 (0.6-1.0) | 0.5 (0.5-1.0) | 0.5 (0-1.0) | 0 (0-0.4) | T0 vs T4: 0.001 T0 vs T12: < 0.001 T0 vs T24: < 0.001 T0 vs T36: 0.002 |
| Daily GC dosagec, mg | 7.3 (5-10) | 5 (5-8.1) | 5 (5-7.2) | 5 (2.5-7.5) | 5 (0.6-5.7) | T0 vs T4: 0.045 T0 vs T12: 0.04 T0 vs T24: 0.049 T0 vs T36: NS |
Values are median (IQR).
↵a Only patients with mucocutaneous involvement at baseline.
↵b Only patients with joint involvement at baseline.
↵c Prednisone equivalent.
↵* Paired samples Wilcoxon rank-sum test. CLASI-A: Cutaneous Lupus Erythematosus Disease Area and Severity Index–activity; GC: glucocorticoid; NS: not significant; PGA: physician global assessment; SJC: swollen joint count; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; SLE-DAS: Systemic Lupus Erythematosus–Disease Activity Score; T: week; TJC: tender joint count.